Mangoceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Mangoceuticals şirketinin toplam hissedar öz sermayesi $13.4M ve toplam borcu $187.5K olup, bu da borç-öz sermaye oranını 1.4% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $14.8M ve $1.4M dir.

Anahtar bilgiler

1.4%

Borç/özkaynak oranı

US$187.50k

Borç

Faiz karşılama oranı	n/a
Nakit	US$90.85k
Eşitlik	US$13.39m
Toplam yükümlülükler	US$1.40m
Toplam varlıklar	US$14.79m

Son finansal sağlık güncellemeleri

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: MGRX 'nin kısa vadeli varlıkları ( $104.1K ) kısa vadeli yükümlülüklerini ( $1.4M ) kapsamıyor.

Uzun Vadeli Yükümlülükler: MGRX şirketinin kısa vadeli varlıkları ( $104.1K ) uzun vadeli yükümlülüklerini ( $12.2K ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: MGRX 'nin net borç/öz sermaye oranı ( 0.7% ) tatmin edici olarak değerlendirilmektedir.

Borcun Azaltılması: MGRX şirketinin borç/öz sermaye oranının son 5 yılda azalıp azalmadığını belirlemek için yeterli veri yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: MGRX son raporlanan serbest nakit akışına göre 0 ay boyunca yeterli nakit pistine sahiptir, ancak o zamandan beri ek sermaye artırmıştır.

Tahmini Nakit Akışı: MGRX serbest nakit akışı tahminlerine göre 0 ay boyunca yeterli nakit akışına sahip olması öngörülüyor, ancak o zamandan beri ek sermaye artırdı.

Mangoceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Mangoceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Mangoceuticals, Inc. Provides Non-Compliance Update

Mangoceuticals, Inc. Receives an Expected Letter from Listing Qualifications Department of The Nasdaq Stock Market LLC

Mangoceuticals Receives Written Notice from The Nasdaq Stock Market LLC Regarding Non-Compliance with the Minimum Bid Price Requirements Set Forth in Nasdaq Listing Rule 5550(a)(2)

Recent updates

Third quarter 2024 earnings released: US$0.99 loss per share (vs US$1.70 loss in 3Q 2023)

Mangoceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Mangoceuticals, Inc. Introduces Oral Tirzepatide GLP-1 Receptor Agonist for Advanced Weight Loss Solutions

Mangoceuticals, Inc. Launches 'Slim' Oral Semaglutide Weight Loss Treatment

Second quarter 2024 earnings released: US$0.092 loss per share (vs US$0.14 loss in 2Q 2023)

Mangoceuticals, Inc. Announces Successful Migration to Its Newly Developed DEA -Approved Telemedicine Operating System

MangoRx Secures DEA Approval for Proprietary HIPAA-Compliant Operating System via Surescripts

Mangoceuticals, Inc.Appoints Dr. Douglas Christianson, N.D. as Director of the Medical Research and Product Innovation Department

Independent Director notifies of intention to sell stock

Mangoceuticals, Inc. Receives Notice of Acceptance for Patent Application in Australia for Respiratory Illness and Preventive Care Technology

Mangorx to Introduce “Mojo” Pharmaceutical Compounded Formula Featuring Enclomiphene Citrate and Pregnenolone for Treatment of Low Testosterone and Male Hormone Imbalances

New major risk - Shareholder dilution

First quarter 2024 earnings released: US$0.10 loss per share (vs US$0.23 loss in 1Q 2023)

Mangoceuticals, Inc., Annual General Meeting, Jun 17, 2024

Mangoceuticals, Inc. Provides Non-Compliance Update

New major risk - Shareholder dilution

New major risk - Financial position

Mangoceuticals, Inc. Officially Launches ‘PRIME’ by MangoRx, Powered by Kyzatrex® FDA Approved Oral Testosterone Replacement Therapy Treatment

Mangoceuticals, Inc. Accepting Pre Orders for its PRIME

High number of new and inexperienced directors

Mangoceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $1.2 million.

Mangoceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $1.2 million.

Mangoceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $1.2 million.

Mangoceuticals, Inc. to Introduce “Prime”, Powered by Kyzatrex® (Ciii Testosterone Undecanoate Capsules), for an FDA Approved Oral Testosterone Replacement Therapy (TRT) Product

Mangoceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $3.6 million.

Mangoceuticals Expands its Men's Health Product Line with Compounded Hair Growth Treatment 'Grow' by MangoRx

Mangoceuticals, Inc. Receives an Expected Letter from Listing Qualifications Department of The Nasdaq Stock Market LLC

Mangoceuticals Receives Written Notice from The Nasdaq Stock Market LLC Regarding Non-Compliance with the Minimum Bid Price Requirements Set Forth in Nasdaq Listing Rule 5550(a)(2)

New major risk - Share price stability

New major risk - Market cap size

Mangoceuticals, Inc. Launches New Sildenafil Based Erectile Dysfunction Product with Signature Mango Flavor & Rapid Dissolve

Mangoceuticals, Inc. Announces Upcoming Launch of Its Sildenafil Based Mango Flavored Rapid Dissolve ED Product

Mangoceuticals, Inc. Appoints Aaron Andrew to Its Advisory Board

Mangoceuticals, Inc. Appoints Amanda Hammer as New Chief Operating Officer

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin